BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalva SP, Pectasides M, Yeddula K, Ganguli S, Blaszkowsky LS, Zhu AX. Factors Affecting Survival following Chemoembolization with Doxorubicin-eluting Microspheres for Inoperable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2013;24:257-65. [DOI: 10.1016/j.jvir.2012.10.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Deipolyi AR, Oklu R, Al-Ansari S, Zhu AX, Goyal L, Ganguli S. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2015;26:516-522. [PMID: 25704226 DOI: 10.1016/j.jvir.2014.12.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
2 Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017;12:e0170750. [PMID: 28170405 DOI: 10.1371/journal.pone.0170750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Reis SP, Sutphin PD, Singal AG, Grzybowski R, Fisher S, Ball C, Xi Y, Grewal S, Kalva SP. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma. J Comput Assist Tomogr 2017;41:289-93. [PMID: 27824665 DOI: 10.1097/RCT.0000000000000509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study. Radiol Med 2020;125:98-106. [PMID: 31583558 DOI: 10.1007/s11547-019-01093-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort. J Vasc Interv Radiol. 2013;24:1639-1646. [PMID: 23962438 DOI: 10.1016/j.jvir.2013.06.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]